PARTNERING
Conditionally hypoimmunogenic cells. Facilitating allogeneic product development with improved safety profiles.
Programmed cell differentiation. Consistent product quality and quantity in stem cell-derived allogeneic therapeutics.
Conditional tissues responses for programmable immunotherapies. Programmed immune effectors cells for oncology.
Programmed viral resistance. Novel therapeutics resistant to patient viral status, and viral contamination during manufacturing.
To find out more about our technology and discuss partnering opportunities, please get in touch.
© 2024 Laverock Therapeutics - All rights reserved • Terms and Conditions • Privacy Policy